Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer.
The purpose of this research study is to compare the efficacy and safety of EG1206A with Perjeta in combination with trastuzumab and chemotherapy as neoadjuvant treatment for 18 weeks, followed by surgery and subsequent EG1206A or Perjeta in combination with trastuzumab, as adjuvant treatment for 36 weeks.
Early Breast Cancer
DRUG: EG1206A|DRUG: Perjeta
Determination of pathologic complete response (pCR) at time of surgery, • pCR at time of surgery, where pCR is defined as the absence of residual invasive cancer of the complete resected breast specimen (regardless of ductal carcinoma in situ \[DCIS\]) and all sampled sentinel and/or axillary lymph nodes (ypT0/is ypN0), as assessed by central laboratory., At the time of surgery (3-6 weeks after completion of neoadjuvant chemotherapy)
The purpose of this research study is to compare the efficacy and safety of EG1206A with Perjeta in combination with trastuzumab and chemotherapy as neoadjuvant treatment for 18 weeks, followed by surgery and subsequent EG1206A or Perjeta in combination with trastuzumab, as adjuvant treatment for 36 weeks.